TY  - JOUR
AU  - Wiels, Wietse A
AU  - Oomens, Julie E
AU  - Engelborghs, Sebastiaan
AU  - Baeken, Chris
AU  - von Arnim, Christine A F
AU  - Boada, Mercè
AU  - Didic, Mira
AU  - Dubois, Bruno
AU  - Fladby, Tormod
AU  - van der Flier, Wiesje M
AU  - Frisoni, Giovanni B
AU  - Fröhlich, Lutz
AU  - Gill, Kiran Dip
AU  - Grimmer, Timo
AU  - Hildebrandt, Helmut
AU  - Hort, Jakub
AU  - Itoh, Yoshiaki
AU  - Iwatsubo, Takeshi
AU  - Klimkowicz-Mrowiec, Aleksandra
AU  - Lee, Dong Young
AU  - Lleó, Alberto
AU  - Martinez-Lage, Pablo
AU  - de Mendonça, Alexandre
AU  - Meyer, Philipp T
AU  - Kapaki, Elisabeth N
AU  - Parchi, Piero
AU  - Pardini, Matteo
AU  - Parnetti, Lucilla
AU  - Popp, Julius
AU  - Rami, Lorena
AU  - Reiman, Eric M
AU  - Rinne, Juha O
AU  - Rodrigue, Karen M
AU  - Sánchez-Juan, Pascual
AU  - Santana, Isabel
AU  - Sarazin, Marie
AU  - Scarmeas, Nikolaos
AU  - Skoog, Ingmar
AU  - Snyder, Peter J
AU  - Sperling, Reisa A
AU  - Villeneuve, Sylvia
AU  - Wallin, Anders
AU  - Wiltfang, Jens
AU  - Zetterberg, Henrik
AU  - Ossenkoppele, Rik
AU  - Verhey, Frans R J
AU  - Vos, Stephanie J B
AU  - Visser, Pieter Jelle
AU  - Jansen, Willemijn J
AU  - Alcolea, Daniel
AU  - Altomare, Daniele
AU  - Baiardi, Simone
AU  - Baldeiras, Ines
AU  - Bateman, Randall J
AU  - Blennow, Kaj
AU  - Bottlaender, Michel
AU  - den Braber, Anouk
AU  - van Buchem, Mark A
AU  - Byun, Min Soo
AU  - Cerman, Jirí
AU  - Chen, Kewei
AU  - Chipi, Elena
AU  - Day, Gregory S
AU  - Drzezga, Alexander
AU  - Eckerström, Marie
AU  - Ekblad, Laura L
AU  - Epelbaum, Stéphane
AU  - Förster, Stefan
AU  - Fortea, Juan
AU  - Freund-Levi, Yvonne
AU  - Frings, Lars
AU  - Guedj, Eric
AU  - Hausner, Lucrezia
AU  - Hellwig, Sabine
AU  - Huey, Edward D
AU  - Jiménez-Bonilla, Julio F
AU  - Johnson, Keith A
AU  - Juaristi, Ane Iriondo
AU  - Kandimalla, Ramesh
AU  - Paraskevas, George
AU  - Kern, Silke
AU  - Kirsebom, Bjørn-Eivind S
AU  - Kornhuber, Johannes
AU  - Lagarde, Julien
AU  - Landau, Susan M
AU  - Legdeur, Nienke
AU  - Llibre Guerra, Jorge J
AU  - Maserejian, Nancy N
AU  - Marquié, Marta
AU  - Minatani, Shinobu
AU  - Morbelli, Silvia Daniela
AU  - Mroczko, Barbara
AU  - Ntanasi, Eva
AU  - de Oliveira, Catarina Resende
AU  - Olivieri, Pauline
AU  - Orellana, Adelina
AU  - Perrin, Richard J
AU  - Peters, Oliver
AU  - Prabhakar, Sudesh
AU  - Ramakers, Inez H
AU  - Rodríguez-Rodriguez, Eloy
AU  - Ruiz, Agustín
AU  - Rüther, Eckart
AU  - Selnes, Per
AU  - Silva, Dina
AU  - Soininen, Hilkka
AU  - Spiru, Luiza
AU  - Takeda, Akitoshi
AU  - Teichmann, Marc
AU  - Tijms, Betty M
AU  - Teunissen, Charlotte E
AU  - Thompson, Loisa I
AU  - Vogelgsangs, Jonathan
AU  - Vöglein, Jonathan
AU  - Waldemar, Gunhild
AU  - Wallin, Åsa K
AU  - Yannakoulia, Mary
AU  - Yi, Dahyun
AU  - Zettergren, Anna
TI  - Depressive Symptoms and Amyloid Pathology.
JO  - JAMA psychiatry
VL  - 82
IS  - 3
SN  - 2168-622X
CY  - Chicago, Ill.
PB  - AMA
M1  - DZNE-2025-00409
SP  - 296 - 310
PY  - 2025
AB  - Depressive symptoms are associated with cognitive decline in older individuals. Uncertainty about underlying mechanisms hampers diagnostic and therapeutic efforts. This large-scale study aimed to elucidate the association between depressive symptoms and amyloid pathology.To examine the association between depressive symptoms and amyloid pathology and its dependency on age, sex, education, and APOE genotype in older individuals without dementia.Cross-sectional analyses were performed using data from the Amyloid Biomarker Study data pooling initiative. Data from 49 research, population-based, and memory clinic studies were pooled and harmonized. The Amyloid Biomarker Study has been collecting data since 2012 and data collection is ongoing. At the time of analysis, 95 centers were included in the Amyloid Biomarker Study. The study included 9746 individuals with normal cognition (NC) and 3023 participants with mild cognitive impairment (MCI) aged between 34 and 100 years for whom data on amyloid biomarkers, presence of depressive symptoms, and age were available. Data were analyzed from December 2022 to February 2024.Amyloid-β1-42 levels in cerebrospinal fluid or amyloid positron emission tomography scans were used to determine presence or absence of amyloid pathology. Presence of depressive symptoms was determined on the basis of validated depression rating scale scores, evidence of a current clinical diagnosis of depression, or self-reported depressive symptoms.In individuals with NC (mean [SD] age, 68.6 [8.9] years; 5664 [58.2
KW  - Humans
KW  - Female
KW  - Male
KW  - Aged
KW  - Depression
KW  - Middle Aged
KW  - Cross-Sectional Studies
KW  - Cognitive Dysfunction
KW  - Amyloid beta-Peptides: cerebrospinal fluid
KW  - Amyloid beta-Peptides: metabolism
KW  - Positron-Emission Tomography
KW  - Aged, 80 and over
KW  - Adult
KW  - Biomarkers: cerebrospinal fluid
KW  - Peptide Fragments: cerebrospinal fluid
KW  - Apolipoprotein E4: genetics
KW  - Age Factors
KW  - Amyloid beta-Peptides (NLM Chemicals)
KW  - Biomarkers (NLM Chemicals)
KW  - Peptide Fragments (NLM Chemicals)
KW  - amyloid beta-protein (1-42) (NLM Chemicals)
KW  - Apolipoprotein E4 (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:39841452
C2  - pmc:PMC11883504
DO  - DOI:10.1001/jamapsychiatry.2024.4305
UR  - https://pub.dzne.de/record/277426
ER  -